HCID 59441997, compound → HCID 178486656, compound

Participants

Reaction Steps

In a manner analogous to General Protocol III, 2-[(2-{[1-[2-(dimethylamino)-2-oxethyl]-5-(methyloxy)-1H-indol-6-yl]amino}-1H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-6-fluorobenzamide was prepared from 2-({2-chloro-7-[(4-methylphenyl)sulfonyl]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}amino)-6-fluorobenzamide (0.25 g, 0.54 mmol) and 2-[6-amino-5-(methyloxy)-2,3-dihydro-1H-indol-1-yl]-N,N-dimethylacetamide (0.16 g, 0.64 mmol) to afford the title compound (0.016 g, 6% over 3 steps) as a grey solid. LCMS (ESI+) and 1H NMR indicate oxidation of the indoline to the indole. ESIMS (M+H)+=517. 1H NMR (400 MHz, DMSO-d6) δ ppm 2.78 (s, 3 H) 2.98 (s, 3 H) 3.80 (s, 3 H) 4.93 (s, 2 H) 6.19-6.20 (m, 1 H) 6.29-6.30 (m, 1 H) 6.82-6.91 (m, 1 H), 6.94-7.01 (m, 1 H) 7.04-7.11 (m, 2 H) 7.25-7.35 (m, 1 H) 7.60 (s, 1 H) 7.98 (s, 1 H) 8.04 (s, 1H) 8.09 (s, 1 H) 8.45 (d, J=8.42 Hz, 1 H) 10.48 (s, 1 H) 11.23 (s, 1 H).

Provenance & Evidence